|
|
Upfront Briefing
The Supreme Court weighed in on tariff authority with clear read-through to pharma import duties — a reminder that supply-chain math can change faster than your annual pricing deck.
In biotech, the “tape is open” again: Gilead agreed to buy Arcellx for $115/share cash plus a $5 CVR (up to ~$7.8B headline), while MoonLake posted positive Phase 2 topline data for sonelokimab in axial spondyloarthritis — a clean PoC that sets up Phase 3 and regulatory-path discussions.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,909.5 |
+0.7% |
+0.9% |
| Nasdaq 100 |
25,012.6 |
+0.9% |
(0.9%) |
| Russell 2000 |
2,663.8 |
(0.1%) |
+7.3% |
| Healthcare (XLV) |
156.8 |
(0.3%) |
+1.3% |
| Biotech (XBI) |
124.8 |
(1.5%) |
+2.3% |
| Nasdaq Biotech (NBI) |
5,979.5 |
(0.5%) |
+4.8% |
| Clinical Trials (BBC) |
40.8 |
(1.5%) |
+5.9% |
|
- Broader tape leaned “risk-on-lite”: S&P 500 (+0.7%) and Nasdaq 100 (+0.9%) finished higher after the Supreme Court tariff ruling reduced near-term trade overhang.
- Healthcare/biotech still de-risked: XLV (-0.3%), XBI (-1.5%), NBI (-0.5%) — classic “index up, biotech down” day as idiosyncratic headline risk + financing overhang dominated.
- Market data: U.S. close Fri 20-Feb-2026.
The Big 3
|
1
|
Supreme Court curbs emergency tariff powers (pharma import-duty risk shifts, not disappears)
|
-
The Supreme Court invalidated broad tariffs imposed under emergency powers, complicating any “fast path” to sweeping import duties.
-
Why it matters:
For pharma, this shifts tariff risk from “sudden and blunt” to “slower and tool-dependent” — companies with ex-US API/DP exposure may get time to re-source / reprice, while policymakers can still pursue sector-specific actions via other authorities (raising the value of supply-chain optionality).
-
Source:
BioPharma Dive
-
More:
Fierce Pharma
|
|
2
|
Gilead strikes to acquire Arcellx (~$7.8B cash + $5 CVR) to bring anito-cel fully in-house
|
-
Gilead agreed to buy Arcellx for $115/share in cash (implied equity value ~$7.8B) plus a $5 contingent value right tied to anito-cel sales (trigger: ≥$6.0B cumulative global net sales through year-end 2029).
-
Why it matters:
This is a clean read-through that “late-stage, de-risked oncology” still clears Big Pharma’s hurdle rate — and it resets comps for CAR-T/myeloma platforms: once the registrational path is visible, control of manufacturing + commercial economics is worth paying for (CVR structure also signals confidence in peak-sales outcomes).
-
Source:
PR
-
More:
Reuters
|
|
3
|
MoonLake reports positive Phase 2 results for sonelokimab
|
-
MoonLake reported positive topline Phase 2 S-OLARIS data for sonelokimab in axial spondyloarthritis, with 81% of treated patients achieving ASAS40 at Week 12 (n=26), supported by imaging and biomarker readouts.
-
Why it matters:
This is a meaningful PoC de-risk for IL-17A/F biology in axSpA and can lift PoS + justify a faster pivot into Phase 3/reg-path discussions — but the small dataset means the valuation reset ultimately hinges on reproducing magnitude in controlled trials.
-
Source:
PR
|
Everything Else that broke
- US vaccine policy turbulence; ACIP meeting delayed. — BioSpace
- Vanda wins FDA approval for Bysanti in schizophrenia. — Endpoints
- Teva NDA accepted for olanzapine injectable for schizophrenia. — PR
- Ionis ends Alzheimer’s candidate development for Down syndrome. — Endpoints
- Roche gets FDA decision date for giredestrant. — BioPharma Dive
- Sickle cell gene therapies show limited commercial traction. — BioSpace
- Catalent cuts 96 staff at Maryland gene therapy site. — Fierce Pharma
-
EU Commission clears Ranluspec (ranibizumab biosimilar) for retinal diseases; Sandoz plans launch in H2 2026. —
EU register
- EMA opens recruitment for next Executive Director. — EMA
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
-
Gilead ↔ Arcellx: $115/share cash (~$7.8B equity value) + $5 CVR (sales-triggered). —
PR
- Novartis to divest India unit for $159M. — Endpoints
-
Harbour BioMed ↔ Solstice Oncology: ex-Greater China rights to HBM4003; >$105M upfront value ($50M cash + $5M near-term + >$50M equity) + up to ~$1.1B milestones + royalties. —
PR
VC / Private Financings
- No notable new venture rounds announced since Friday’s close (in our scan).
IPOs / Follow-Ons
- Eupraxia closes US$63.2M public offering. — PR
|
|
That’s it for today — may your endpoints be met, your takeout premiums be cash (not CVRs), and your tariffs remain hypothetical. See you tomorrow. BioBucks Team
|
|
|
